Reduced L-selectin (CD62LLow) expression identifies tumor-specific type 1 T cells from lymph nodes draining an autologous tumor cell vaccine.
Data(s) |
2004
|
---|---|
Resumo |
Reduced expression of CD62L can identify tumor-specific T cells in lymph nodes draining murine tumors. Here, we examined whether this strategy could isolate tumor-specific T cells from vaccinated patients. Tumor vaccine-draining lymph node (TVDLN) T cells of seven patients were separated into populations with reduced (CD62LLow) or high levels of CD62L (CD62LHigh). Effector T cells generated from CD62LLow cells maintained or enriched the autologous tumor-specific type 1 cytokine response compared to unseparated TVDLN T cells in four of four patients showing tumor-specific cytokine secretion. Interestingly, effector T cells generated from CD62LLow or CD62LHigh TVDLN were polarized towards a dominant type 1 or type 2 cytokine profile, respectively. For CD62LLow T cells the type 1 cytokine profile appeared determined prior to culture. Since a tumor-specific type 1 cytokine profile appears critical for mediating anti-tumor activity in vivo, this approach might be used to isolate T cells for adoptive immunotherapy. |
Identificador |
http://serval.unil.ch/?id=serval:BIB_3771552B28C2 isbn:0008-8749 pmid:15135291 doi:10.1016/j.cellimm.2004.01.006 isiid:000221528600002 |
Idioma(s) |
en |
Fonte |
Cellular Immunology, vol. 227, no. 2, pp. 93-102 |
Palavras-Chave | #Cancer Vaccines/immunology; Carcinoma, Renal Cell/immunology; Carcinoma, Renal Cell/therapy; Humans; Immunotherapy, Adoptive; Interferon-gamma/biosynthesis; Interleukin-5/biosynthesis; Kidney Neoplasms/immunology; Kidney Neoplasms/therapy; L-Selectin/analysis; Lymph Nodes/immunology; Melanoma/immunology; Melanoma/therapy; T-Lymphocytes/immunology |
Tipo |
info:eu-repo/semantics/article article |